Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 ...

This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational ...

In the publication, the authors describe the long-term properties of a human stem-cell derived GABAergic interneuron cell therapy, the clinical-grade version of which, called NRTX-1001, is currently ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ...

Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini ...

ISS and Glass Lewis are leading U.S. institutional voting advisory services that regularly publish analyses on public shareholder votes. Inmagene is a privately held, clinical stage biopharmaceutical ...

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635 ...

The effects of arimoclomol in mutant NPC cells found across the in vitro studies are consistent, and downstream effects expected to result from the activation of a specific process in one study could ...

Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer’s disease ...

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth ...

Heartflow Plaque Analysis is the only FDA-cleared, AI-enabled plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, in a prospective, global trial using blinded core ...